Toggle navigation
About Us
Science & Innovation
Products and Resources
Our Responsibility
Careers
Investors
Media
Toggle navigation
Press Releases
Featured News
Press Statements
Subscribe
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Jun 29, 2022
Sanofi to lower out-of-pocket cost of insulin for uninsured patients and expand access in underserved communities
Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins
Jun 22, 2022
Sanofi Statement on ACIP 2022-2023 Influenza Recommendations for People 65+
Jun 22, 2022
Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older
Results of nationally representative survey come as the ACIP evaluates data to provide guidance for flu vaccines in this vulnerable population
Jun 7, 2022
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Jun 7, 2022
Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing
Show
5
10
25
50
100
per page
«
1
…
5
6
7
8
9
10
11
…
189
»
Print
Email page
RSS